Physician profile
Noha R Barsoum
NPI 1053391185
$1,721.73
in general payments reported to CMS, 2019-2025
23 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $224 · 2023: $13.60 · 2024: $98.35 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.32 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $428.14 | 2019-2025 | Otezla, Repatha, Tavneos |
| Otsuka America Pharmaceutical, INC. | $356.12 | 2019-2025 | Jynarque |
| Philips North America LLC | $200.11 | 2019-2020 | |
| Dexcom, INC. | $104.13 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $69.96 | 2019-2024 | Wegovy, Saxenda |
| Mallinckrodt Enterprises LLC | $60.86 | 2019 | |
| Vertiflex, INC. | $56.59 | 2019 | |
| Horizon Therapeutics Plc | $51.58 | 2019-2020 | |
| Astellas Pharma US INC | $50.25 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $40.56 | 2019 | |
| Genzyme Corporation | $37.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $34.27 | 2024 | Benlysta |
| Vifor Pharma, INC. | $31.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.48 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $23.83 | 2019 | |
| Gilead Sciences, INC. | $20.15 | 2019 | |
| Boston Scientific Corporation | $19.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.33 | 2019 | |
| Fresenius USA Marketing, INC. | $16.87 | 2019 | |
| Merck Sharp & Dohme LLC | $16.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.03 | 2020 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noha Barsoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.